Why Novo Nordisk Stock Just Crashed

Novo Nordisk (NYSE: NVO) is taking it connected the chin this morning, aft revealing the latest objective proceedings results for value nonaccomplishment utilizing its CagriSema cause (a 50-50 premix of amylin analog cagrilintide and Novo's glucagon-like peptide-1 (GLP-1) receptor agonist). After an 84-week trial, Novo reported that its patients achieved 23% value nonaccomplishment with the drug.

That sounds similar beauteous bully news, but investors don't look to similar the fig -- and arsenic of 10:10 a.m. ET, Novo Nordisk banal is down 14.8%.

Where to put $1,000 close now? Our expert squad conscionable revealed what they judge are the 10 champion stocks to bargain close now, erstwhile you articulation Stock Advisor. See the stocks »

Why are investors upset? Basically, due to the fact that the constituent of the proceedings was for Novo Nordisk to show that a 2.4/2.4 mg dose of CagriSema could outperform a 15 mg dose of tirzepatide (the progressive constituent successful Eli Lilly's (NYSE: LLY) Zepbound and Mounjaro aft 84 weeks' usage.

But it didn't.

809 radical afflicted with some obesity and astatine slightest 1 comorbidity participated successful the trial. At the endpoint, those taking CagriSema mislaid an mean of 23% of their assemblage value (which started astatine 114.2 kg connected average). Those taking Eli Lilly's GLP-1 cause mislaid 25.5%.

Novo Nordisk says it was "pleased with the value nonaccomplishment of 23% for CagriSema," and inactive plans to proceed to a "higher-dose CagriSema trial." But for present astatine least, the atrocious quality is that Novo's wonder-drug -- portion inactive objectively fantastic -- is simply a spot little astonishing than Eli Lilly's Zepbound and Mounjaro.

At past report, Novo Nordisk had forecast that its income and net would some diminution 5% to 13% successful 2026. Investors had been hoping that affirmative findings connected CagriSema mightiness assistance Novo to bounce backmost quickly. With CagriSema's prospects present dimming, investors whitethorn request to hold a spot longer for a rebound.

Before you bargain banal successful Novo Nordisk, see this:

The Motley Fool Stock Advisor expert squad conscionable identified what they judge are the 10 champion stocks for investors to bargain now… and Novo Nordisk wasn’t 1 of them. The 10 stocks that made the chopped could nutrient monster returns successful the coming years.

Consider erstwhile Netflix made this database connected December 17, 2004... if you invested $1,000 astatine the clip of our recommendation, you’d person $424,262!* Or erstwhile Nvidia made this database connected April 15, 2005... if you invested $1,000 astatine the clip of our recommendation, you’d person $1,163,635!*